Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSMED IncINSM · Entity 3174 | Director · Chair and CEO | July 23, 2026 | July 24, 2026 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Director | January 07, 2026 | January 10, 2026 |
| uniQure N.V.QURE · Entity 4162 | Director | January 27, 2017 | January 31, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSMED Inc
Report date July 23, 2026 · Filed July 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 259,058 |
Ending reported balance
After 2026-07-23 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-07-23 · Exercise / conversion · Acquired 6,260 · Balance 265,318 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 2 · 2026-07-23 · Exercise / conversion · Acquired 4,440 · Balance 269,758 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 3 · 2026-07-23 · Sale · Disposed 4,828 · Balance 264,930 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Row 4 · 2026-07-23 · Sale · Disposed 5,872 · Balance 259,058 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.46 · Expires 2028-01-04 | Direct | 0 |
Reported balance
After 2026-07-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-23 · Exercise / conversion · Disposed 6,260 · Balance 0 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.16 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2026-07-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-23 · Exercise / conversion · Disposed 4,440 · Balance 0 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 233,924 |
Reported balance
Holding disclosure · report date 2026-07-23 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 233,924 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F3: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
NewAmsterdam Pharma Co N.V.
Report date January 07, 2026 · Filed January 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,360 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 3,400 · Balance 10,360 F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2: Each RSU was granted on January 7, 2026 for no consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.45 · Expires 2036-01-07 | Direct | 15,300 |
Reported balance
After 2026-01-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-07 · Grant · Acquired 15,300 · Balance 15,300 F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
F2: Each RSU was granted on January 7, 2026 for no consideration.
F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
uniQure N.V.
Report date January 27, 2017 · Filed January 31, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.37 · Expires 2027-01-27 | Direct | 11,000 |
Reported balance
After 2017-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-27 · Grant · Acquired 11,000 · Balance 11,000 F1: The Stock Option vests 100% on January 27, 2018. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 16,000 |
Reported balance
After 2017-01-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-27 · Grant · Acquired 11,000 · Balance 16,000 F2: The Restricted Stock Unit vests 100% on January 27, 2018. F3: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option vests 100% on January 27, 2018.
F2: The Restricted Stock Unit vests 100% on January 27, 2018.
F3: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 315 | $174.86 | $55,080.90 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 306,891 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 297 | $172.36 | $51,190.92 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,206 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: This is the weighted average sales price representing 297 shares sold at prices ranging from $172.26 to $172.42 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 297 | $171.31 | $50,879.07 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,503 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 297 shares sold at prices ranging from $171.21 to $171.52 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 160 | $170.24 | $27,238.40 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,800 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 160 shares sold at prices ranging from $170.12 to $170.89 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 6,996 | $169.57 | $1,186,311.72 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,960 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 6,996 shares sold at prices ranging from $169.11 to $170.08 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 7,176 | $168.63 | $1,210,088.88 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,956 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 7,176 shares sold at prices ranging from $168.11 to $169.10 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,974 | $167.73 | $666,559.02 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 322,132 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 3,974 shares sold at prices ranging from $167.11 to $168.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 4,440 | $17.16 | $76,190.40 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 326,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,259 | $30.46 | $190,649.14 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 321,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 08, 2026 Filed Jan 8, 2026 22:20 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,223 | $174.17 | $561,349.91 |
DisclosureSEC source: 0001402051-26-000005 · wk-form4_1767910807.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,407 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:20 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,357 | $175.07 | $412,639.99 |
DisclosureSEC source: 0001402051-26-000005 · wk-form4_1767910807.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 318,630 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 00:34 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 15,300 | $0.00 Strike: $35.45 | $0.00 |
DisclosureSEC source: 0001193125-26-009271 · ownership.xml · derivative · entry 2 Lewis William · CIK 0001402051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,300 Underlying: Ordinary Shares · 15,300 shares Expires 2036-01-07 F3 · derivative.exercise_date: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 00:34 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOrdinary Shares | 3,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-009271 · ownership.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,360 F1 · shares: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2 · price: Each RSU was granted on January 7, 2026 for no consideration. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:20 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 4,096 | $173.33 | $709,959.68 |
DisclosureSEC source: 0001402051-26-000005 · wk-form4_1767910807.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,987 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:07 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 110,400 | $0.00 Strike: $177.12 | $0.00 |
DisclosureSEC source: 0001402051-26-000003 · wk-form4_1767733634.xml · derivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,400 Underlying: Common Stock · 110,400 shares Expires 2036-01-02 F3 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:07 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 21,172 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001402051-26-000003 · wk-form4_1767733634.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,083 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. F2 · price: Each RSU was granted on January 2, 2026 for no consideration. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:12 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,259 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · derivative · entry 16 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,627 Underlying: Common Stock · 6,259 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:12 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 4,440 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · derivative · entry 15 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,160 Underlying: Common Stock · 4,440 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F12 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:12 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 51 | $171.20 | $8,731.20 |
DisclosureSEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 12 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 303,911 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F11 · price: This is the weighted average sales price representing 51 shares sold at prices ranging from $171.09 to $171.35 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:12 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 362 | $170.26 | $61,634.12 |
DisclosureSEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 11 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 303,962 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F10 · price: This is the weighted average sales price representing 362 shares sold at prices ranging from $170.02 to $170.91 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:12 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,938 | $169.58 | $328,646.04 |
DisclosureSEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 10 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 304,324 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F9 · price: This is the weighted average sales price representing 1,938 shares sold at prices ranging from $169.01 to $170.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:12 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,175 | $168.54 | $366,574.50 |
DisclosureSEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 306,262 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · price: This is the weighted average sales price representing 2,175 shares sold at prices ranging from $168.01 to $169.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:12 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,431 | $167.29 | $239,391.99 |
DisclosureSEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,437 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: This is the weighted average sales price representing 1,431 shares sold at prices ranging from $167.00 to $167.95 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:12 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,783 | $166.60 | $297,047.80 |
DisclosureSEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,868 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 1,783 shares sold at prices ranging from $166.00 to $166.99 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:12 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 697 | $165.21 | $115,151.37 |
DisclosureSEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 311,651 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 697 shares sold at prices ranging from $164.83 to $165.67 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:12 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 447 | $164.24 | $73,415.28 |
DisclosureSEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 312,348 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 447 shares sold at prices ranging from $163.75 to $164.73 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:12 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,465 | $163.19 | $239,073.35 |
DisclosureSEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 312,795 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 1,465 shares sold at prices ranging from $162.72 to $163.62 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:12 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 350 | $162.26 | $56,791.00 |
DisclosureSEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,260 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 350 shares sold at prices ranging from $161.72 to $162.69 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:12 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,259 | $30.46 | $190,649.14 |
DisclosureSEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 21:12 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 4,440 | $17.16 | $76,190.40 |
DisclosureSEC source: 0001628280-25-058269 · wk-form4_1766178755.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:11 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 4,440 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001402051-25-000009 · wk-form4_1764969079.xml · derivative · entry 10 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,600 Underlying: Common Stock · 4,440 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:11 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,259 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001402051-25-000009 · wk-form4_1764969079.xml · derivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,886 Underlying: Common Stock · 6,259 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:11 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,040 | $207.42 | $215,716.80 |
DisclosureSEC source: 0001402051-25-000009 · wk-form4_1764969079.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 303,911 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 1.040 shares sold at prices ranging from $207.20 to $207.73 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:11 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,921 | $206.49 | $603,157.29 |
DisclosureSEC source: 0001402051-25-000009 · wk-form4_1764969079.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 304,951 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 2,921 shares sold at prices ranging from $206.15 to $207.13 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:11 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,222 | $205.66 | $456,976.52 |
DisclosureSEC source: 0001402051-25-000009 · wk-form4_1764969079.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,872 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 2,222 shares sold at prices ranging from $205.11 to $206.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:11 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 4,516 | $204.62 | $924,063.92 |
DisclosureSEC source: 0001402051-25-000009 · wk-form4_1764969079.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 310,094 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 4,516 shares sold at prices ranging from $204.01 to $204.98 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:11 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 4,440 | $17.16 | $76,190.40 |
DisclosureSEC source: 0001402051-25-000009 · wk-form4_1764969079.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:11 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,259 | $30.46 | $190,649.14 |
DisclosureSEC source: 0001402051-25-000009 · wk-form4_1764969079.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 310,170 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:28 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,865 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001402051-25-000007 · wk-form4_1755721724.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 0 Underlying: Common Stock · 6,865 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:28 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,416 | $129.47 | $183,329.52 |
DisclosureSEC source: 0001402051-25-000007 · wk-form4_1755721724.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 1,416 shares sold at prices ranging from $129.26 to $129.95 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:28 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,481 | $128.76 | $319,453.56 |
DisclosureSEC source: 0001402051-25-000007 · wk-form4_1755721724.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 235,340 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 2,481 shares sold at prices ranging from $128.26 to $129.21 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:28 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,968 | $127.59 | $378,687.12 |
DisclosureSEC source: 0001402051-25-000007 · wk-form4_1755721724.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 237,821 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 2,968 shares sold at prices ranging from $127.20 to $128.16 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:28 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,865 | $10.85 | $74,485.25 |
DisclosureSEC source: 0001402051-25-000007 · wk-form4_1755721724.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:21 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001402051-25-000004 · wk-form4_1754511692.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 6,865 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:21 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,938 | $110.91 | $214,943.58 |
DisclosureSEC source: 0001402051-25-000004 · wk-form4_1754511692.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 1,938 shares sold at prices ranging from $110.26 to $111.24 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:21 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,199 | $109.68 | $350,866.32 |
DisclosureSEC source: 0001402051-25-000004 · wk-form4_1754511692.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 235,862 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 3,199 shares sold at prices ranging from $109.25 to $110.23 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:21 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,693 | $108.80 | $184,198.40 |
DisclosureSEC source: 0001402051-25-000004 · wk-form4_1754511692.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 239,061 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 1,693 shares sold at prices ranging from $108.24 to $109.23 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| August 04, 2025 Filed Aug 6, 2025 20:21 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001402051-25-000004 · wk-form4_1754511692.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 15, 2025 Filed Jul 15, 2025 21:53 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001104506-25-000030 · wk-form4_1752616402.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 13,695 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| July 15, 2025 Filed Jul 15, 2025 21:53 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 170 | $103.32 | $17,564.40 |
DisclosureSEC source: 0001104506-25-000030 · wk-form4_1752616402.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 170 shares sold at prices ranging from $103.14 to $103.37 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.